Drug · CHEMBL702
PIPERACILLIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PIPERACILLIN. Drugs and targets, record CHEMBL702. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL702
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Peracin, Piperacilina, Piperacillin anhydrous, Piperacillin hydrate, Piperacillin monohydrate, Piperacillin, anhydrous, Piperacilline
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases33
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 33Source Open Targets
See all 33 diseasesTrials122
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05094154 | Effect of Antibiotic Choice On ReNal Outcomes (ACORN) | Phase 4 | 2,634 | 2023-12-22 | piperacillin | Its name | ClinicalTrials.gov |
| NCT03269994 | Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? | Phase 3 | 967 | 2025-10-21 | piperacillin-tazobactam | A combination that names it | ClinicalTrials.gov |
| NCT01370616 | Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061) | Phase 3 | 565 | 2014-12-02 | piperacillin | Its name | ClinicalTrials.gov |
| NCT02753946 | Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections | Phase 2/3 | 465 | 2018-12-11 | piperacillin | Its name | ClinicalTrials.gov |
| NCT03019965 | Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis | 426 | 2021-08-05 | piperacillin/tazobactam | A combination that names it | ClinicalTrials.gov | |
| NCT01994993 | Antibiotic Safety (SCAMP) | Phase 2/3 | 260 | 2018-02-27 | piperacillin-tazobactam | A combination that names it | ClinicalTrials.gov |
| NCT03289351 | Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis | Phase 4 | 162 | 2024-01-12 | piperacillin | Its name | ClinicalTrials.gov |
| NCT03159754 | Optimal Care of Complicated Appendicitis | Phase 4 | 40 | 2023-11-28 | piperacillin-tazobactam | A combination that names it | ClinicalTrials.gov |
| NCT02991937 | Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children | Phase 4 | 39 | 2022-01-21 | piperacillin/tazobactam | A combination that names it | ClinicalTrials.gov |
| NCT05102162 | BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia | Phase 4 | 35 | 2023-12-12 | piperacillin/tazobactam | A combination that names it | ClinicalTrials.gov |
1 to 10 of 122
See all 122 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: Major Adverse Kidney Events Within 14 Days (MAKE14) | 124 of 1,214 | 114 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause | 104 of 1,214 | 106 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: serious adverse events | 0 of 1,214 | 0 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Cefoxitin vs Piperacillin-tazobactam: Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | 400 of 400 | 378 of 378 | 778 | NCT03269994 | Trial comparisons |
| Cefoxitin vs Piperacillin-tazobactam: deaths from any cause | 10 of 400 | 5 of 378 | 778 | NCT03269994 | Trial comparisons |
| Cefoxitin vs Piperacillin-tazobactam: serious adverse events | 10 of 400 | 5 of 378 | 778 | NCT03269994 | Trial comparisons |
| Ertapenem Sodium vs Piperacillin/Tazobactam Sodium: serious adverse events | 17 of 275 | 12 of 275 | 550 | NCT01370616 | Trial comparisons |
| ZTI-01 vs Piperacillin Tazobactam: deaths from any cause | 0 of 233 | 0 of 231 | 464 | NCT02753946 | Trial comparisons |
| ZTI-01 vs Piperacillin Tazobactam: serious adverse events | 5 of 233 | 6 of 231 | 464 | NCT02753946 | Trial comparisons |
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: Number of Participants With Clinical Response | 178 of 201 | 169 of 202 | 403 | NCT03019965 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials85
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL702
GET https://conductscience.org/api/drugs/v1/CHEMBL702/diseases?page=2